Successful combination treatment with rituximab, steroid pulse therapy, plasma exchange and romiplostim for very severe TAFRO syndrome

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors thank the patient and clinical staff at Wakayama Medical University Hospital for their participation in this study. The authors also thank Dr. Hiroshi Kawabata from the National Hospital Organization Kyoto Medical Center for his helpful clinical support.

Ethical approval

All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the relevant institutional and/or national research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient. This case report was approved by the ethics committee of Wakayama Medical University (No. 3473).

Author contributions

Hiroki Hosoi designed the study. Ayaka Sakaki, Hiroki Hosoi, Hideki Kosako, Yoshiaki Furuya, and Ryuta Iwamoto collected the data. Ayaka Sakaki and Hiroki Hosoi wrote the manuscript. Takayuki Hiroki, Shogo Murata, and Toshiki Mushino critically reviewed the results and edited the manuscript. Shin-Ichi Murata and Takashi Sonoki supervised the study. All of the authors approved the final submitted version of the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This study was supported by the Japan Society for the Promotion of Science (JSPS) [KAKENHI Grant Number 21K16248 to HH].